We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIAZYME LABORATORIES

Diazyme develops diagnostic reagents using its proprietary enzyme technologies that can be used on most automated che... read more Featured Products: More products

Download Mobile App




Performance of Five Lipoprotein(a) Immunoassays Evaluated

By LabMedica International staff writers
Posted on 06 Apr 2021
Print article
Image: The Diazyme Lipoprotein A assay kit is for the in vitro quantitative determination of Lp(a) concentration in human serum or plasma on Clinical Chemistry Systems (Photo courtesy of Diazyme)
Image: The Diazyme Lipoprotein A assay kit is for the in vitro quantitative determination of Lp(a) concentration in human serum or plasma on Clinical Chemistry Systems (Photo courtesy of Diazyme)
Increased serum Lipoprotein(a) [Lp(a)] is considered an independent, inherited risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and stroke. This risk is believed to be due to pro-atherogenic, pro-inflammatory, and pro-thrombotic properties of the Lp(a) particle.

Lp(a) can be measured using a variety of methods, including enzyme linked immunosorbent assays (ELISA), latex-agglutination, immunoturbidimetry/immunonephelometry, electrophoresis, and immunofixation electrophoresis (IFE). A confounding factor is that Lp(a) can be reported in either mass units (mg/dL of the total Lp(a) particle) or molar concentration of particles (nmol/L).

Medical Laboratorians at the ARUP Institute of Clinical and Experimental Pathology (Salt Lake City, UT, USA) and their colleagues used 80 residual serum samples, and specimens from 120 self-reported healthy subjects (61 females/59 males) were also tested in a study. The aim of the study was to evaluate performance characteristic of five different Lp(a) assays using the cobas c501 analyzer (Roche Diagnostics, Indianapolis, IN, USA).

The five assay for Lp(a) used were from: Diazyme (Poway, CA, USA), Kamiya Biomedical Company (Seattle, WA, USA), MedTest Dx (Canton, MI, USA), Randox Laboratories (Crumlin, UK) and Roche Diagnostics, configured to mg/dL units. Assays from Diazyme and Kamiya were also configured using nmol/L units in separate studies. Studies included sensitivity, imprecision, linearity, method comparison, and evaluation of healthy subjects. Imprecision (intra-day, 20 replicates; inter-day, duplicates twice daily for five days) and linearity were evaluated using patient pools. Linearity assessed a minimum of five patient splits spanning the analytical measurement range (AMR).

The scientists reported that all methods met manufacturer claims regarding sensitivity: observed (manufacturer claim): Diazyme, 0.7 mg/dL (1.3 mg/dL); Kamiya, 1.2 mg/dL (5.0 mg/dL); MedTest, 0.2 mg/dL (1.3 mg/dL); Randox, 0.7 mg/dL (3.0 mg/dL); Roche, 0.3 mg/dL (4.0 mg/dL). Lp(a) assays also demonstrated acceptable imprecision and met manufacturers’ claims, with CVs less than 6% in all cases. Imprecision studies demonstrated %CVs ranging from 2.5 – 5.2% for the low pool (average concentration from 7.3 – 12.4 mg/dL); high pool %CVs ranged from 0.8 – 3.0% (average concentrations from (31.5 – 50.2 mg/dL). Linearity was confirmed for all assays. Variation in accuracy was observed when comparing results to an all method average. Lp(s) results were higher in females versus males in self-reported healthy subjects.

The authors concluded that all assays performed according to manufacturer described performance characteristics, although differences were observed across Lp(a) assays tested when compared to an all method average. The study was published on March 24, 2021 in the journal Practical Laboratory Medicine.

Related Links:
ARUP Institute of Clinical and Experimental Pathology
Roche Diagnostics
Diazyme
Kamiya Biomedical Company
MedTest Dx
Randox Laboratories


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.